Suven Life Sciences Ltd vs Thyrocare Technologies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Suven Life Sciences Ltd is ₹ 261.8 as of 23 Oct 15:30 . The P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 years The Market Cap of Suven Life Sciences Ltd changed from ₹ 896.07 crore on March 2021 to ₹ 3503 crore on March 2026 . This represents a CAGR of 25.51% over 6 yearsThe Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 years The revenue of Suven Life Sciences Ltd for the Jun '26 is ₹ 11.09 crore as compare to the Mar '26 revenue of ₹ 8.3 crore. This represent the growth of 33.61% The revenue of Thyrocare Technologies Ltd for the Jun '26 is ₹ 244.88 crore as compare to the Mar '26 revenue of ₹ 228.84 crore. This represent the growth of 7.01% The ebitda of Suven Life Sciences Ltd for the Jun '26 is ₹ -124 crore as compare to the Mar '26 ebitda of ₹ -43.86 crore. This represent the growth of 184.95% The ebitda of Thyrocare Technologies Ltd for the Jun '26 is ₹ 82.13 crore as compare to the Mar '26 ebitda of ₹ 79.98 crore. This represent the growth of 2.69% The net profit of Suven Life Sciences Ltd changed from ₹ -28.04 crore to ₹ -127 crore over 9 quarters. This represents a CAGR of 96.11% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 51.33 crore over 9 quarters. This represents a CAGR of 40.35% The Dividend Payout of Suven Life Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 years .

About Suven Life Sciences Ltd

Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989.
The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003.
Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider. The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies. The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors.

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

FAQs for the comparison of Suven Life Sciences Ltd and Thyrocare Technologies Ltd

Which company has a larger market capitalization, Suven Life Sciences Ltd or Thyrocare Technologies Ltd?

Market cap of Suven Life Sciences Ltd is 7,397 Cr while Market cap of Thyrocare Technologies Ltd is 7,357 Cr

What are the key factors driving the stock performance of Suven Life Sciences Ltd and Thyrocare Technologies Ltd?

The stock performance of Suven Life Sciences Ltd and Thyrocare Technologies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Life Sciences Ltd and Thyrocare Technologies Ltd?

As of October 25, 2026, the Suven Life Sciences Ltd stock price is INR ₹261.8. On the other hand, Thyrocare Technologies Ltd stock price is INR ₹462.25.

How do dividend payouts of Suven Life Sciences Ltd and Thyrocare Technologies Ltd compare?

To compare the dividend payouts of Suven Life Sciences Ltd and Thyrocare Technologies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.